首页 > 市场调查报告书 > 製药

癌症生物标记

市场调查报告书

商品编码

2010888

粒细胞集落刺激因子（GNLY）市场报告：趋势、预测和竞争分析（至2035年）

Granulysin (GNLY) Market Report: Trends, Forecast and Competitive Analysis to 2035

出版日期: 2026年04月07日 | 出版商:

Lucintel | 英文 161 - page report | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录图表

受医疗和实验领域机会的推动，全球颗粒蛋白（GNLY）市场前景光明。预计2026年至2035年，全球颗粒蛋白（GNLY）市场将以10.6%的复合年增长率成长，到2035年市场规模预计将达到15.12亿美元。推动该市场成长的关键因素包括生物技术公司与研究机构之间合作的日益密切、GNLY生物标记在诊断检测中的应用不断广泛，以及癌症治疗研究中对颗粒蛋白的需求不断增长。

根据 Lucintel 的预测，按类型划分，9 kDa 的 GNLY 预计在预测期内将呈现较高的成长率。
从应用角度来看，医学科学领域预计将呈现更高的成长率。
从区域来看，预计亚太地区在预测期内将呈现最高的成长率。

粒细胞集落刺激因子（GNLY）市场的新发展

受免疫学、生物技术和个人化医疗领域进步的推动，颗粒蛋白（GNLY）市场正迅速发展。随着研究人员对GNLY在免疫反应中的作用了解不断加深，新的诊断和治疗应用也应运而生。市场相关人员正投资于创新研究，以开发针对感染疾病、癌症和发炎性疾病的标靶治疗。此外，监管环境和技术创新正在重塑市场格局，使基于GNLY的解决方案更易于获取且更有效。这些发展不仅扩大了市场，也改变了医疗专业人员应对免疫相关疾病的方式，最终将带来更个人化和有效的患者照护。

研发活动活性化：人们对GNLY在免疫反应中的作用日益浓厚的科学兴趣正在推动研发工作。研究人员正在探索GNLY作为疾病诊断和预后生物标记以及治疗标靶的潜力。这一趋势正在推动新型诊断工具和治疗方法的开发，并吸引了生物技术公司和学术机构的投资。不断扩大的研发活动可望加速新应用领域的发现，进而拓宽市场范围并改善患者预后。
感染疾病和自体免疫免疫疾病的日益普及：结核病、病毒感染疾病等感染疾病以及自体免疫疾病在全球范围内的增加，推动了对基于GNLY的诊断和治疗方法的需求。 GNLY调节免疫反应的能力使其成为治疗这些疾病的理想候选药物。随着人们对这些疾病的认识不断提高，诊断能力不断增强，医疗系统也在寻求更有效的解决方案，预计GNLY相关产品的市场将显着成长。这一趋势凸显了GNLY在满足未被满足的医疗需求方面的重要作用。
生物标记检测技术的进步：检测方法的创新，包括高通量筛检和多重检测技术，正在提高GNLY的检测和定量准确性。这些技术进步能够实现更准确、快速且经济高效的诊断，从而促进疾病的早期发现和个人化治疗方案的发展。随着这些工具的普及，临床决策将得到改进，GNLY在常规医疗保健中的应用范围也将扩大，最终将推动市场成长和应用。
个人化医疗日益受到重视：随着医疗模式向个人化转变，免疫生物标记（如GNLY）在以患者为中心的治疗中变得日益重要。了解个人免疫特征有助于临床医生优化感染疾病、癌症和发炎性疾病的治疗方法。这一趋势正在推动个人化治疗方法的发展，并增加对GNLY检测和标靶治疗的需求。因此，市场正朝着更精准、更具个人化的解决方案转型，这些方案有望提高疗效并减少副作用。
法规环境与市场拓展：监管机构日益认识到免疫生物标记的重要性，基于GNLY的诊断和治疗方法的核准路径也日益清晰。同时，在医疗保健投资增加和基础建设的推动下，新兴市场对这些创新技术表现出浓厚的兴趣。监管支援和市场拓展正在加速GNLY相关产品的商业化和广泛应用。因此，市场竞争日益激烈，进入门槛降低，促进了创新和全球成长。

这些趋势正透过促进创新、拓展应用领域以及改进诊断和治疗方案，全面重塑粒细胞微粒体（GNLY）市场。对个人化医疗的关注、技术进步和监管支持正在推动市场成长，并改变免疫相关疾病的医疗保健方法。这种演变有望带来更有效、更有针对性且更容易取得的解决方案，最终改善全球患者照护。

颗粒酶（GNLY）市场的最新趋势

受免疫疗法和感染疾病治疗领域进展的推动，颗粒菌素（GNLY）市场正经历快速成长。随着对GNLY抗菌和抗肿瘤特性的研究日益增多，其应用范围也不断扩大。感染疾病和癌症发生率的上升进一步推动了对基于GNLY治疗方法的需求。药物递送和生物标记识别的技术创新正在提升市场的潜力。监管部门的核准以及生物技术公司之间的合作正在加速产品开发。这些发展共同改变了GNLY的市场格局，开启了新的治疗途径，并改善了全球患者的治疗效果。

GNLY抗菌特性研究进展：这项进展正在拓展GNLY在感染疾病治疗中的应用范围，并有望开发出对抗抗药性病原体的新治疗方法。这将吸引投资，促进抗菌药物领域的创新，重振市场，最终改善全球医疗保健状况，减轻疾病负担。
基于GNLY的免疫疗法取得进展：将GNLY整合到免疫疗法策略中，正在扩展癌症治疗选择。这使得靶向免疫反应成为可能，从而提高治疗效果并减少副作用。这项进展正吸引製药公司的关注，扩大市场规模，并加速肿瘤领域新产品的研发。
感染疾病和癌症发病率上升：爱滋病、结核病和各种癌症等疾病发病率的不断上升，推动了对基于GNLY的解决方案的需求。这一趋势正在扩大诊断和治疗市场，刺激研发投资，并促进合作以满足尚未满足的需求。
药物递送和生物标记鑑定方面的技术创新：新型递送系统和生物标记的发现正在提高GNLY的稳定性、标靶化和疗效。这些创新提高了GNLY疗法的实用性，拓展了临床应用，并吸引了更多资金。这正在加速市场成长并拓宽治疗选择。
监管核准与策略合作：近期核准和合作正在加速基于GNLY技术的产品进入市场。这些进展增强了产品平臺，提升了投资者信心，并加速了商业化进程，这些因素共同推动了市场成长并促进了进一步的创新。

这些趋势的总体影响是形成了一个快速扩张的GNLY市场，其特点是创新治疗方法不断涌现、投资增加以及临床应用范围扩大。预计这种成长将改善患者预后，满足未被满足的医疗需求，并刺激进一步的研究和开发，使GNLY成为未来治疗策略中不可或缺的一部分。

亚太地区颗粒碱（GNLY）市场：按类型划分
亚太地区颗粒碱（GNLY）市场：依应用领域划分
中国粒细胞胞苷（GNLY）市场
印度粒细胞集落刺激因子（GNLY）市场
日本粒细胞胞苷（GNLY）市场
韩国粒细胞胞苷（GNLY）市场
印尼 Granulisin (GNLY) 市场

第十章：世界其他地区粒诺利辛（GNLY）市场

其他地区粒蛋白酶（GNLY）市场：按类型划分
其他地区粒蛋白酶（GNLY）市场：依应用划分
中东粒单胞菌素（GNLY）市场
南非 Granulisine (GNLY) 市场
非洲粒蛋白（GNLY）市场

第十一章竞争分析

产品系列分析
业务整合
波特五力分析
市占率分析

第十二章机会与策略分析

价值链分析
成长机会分析
新趋势：全球颗粒酶（GNLY）市场
战略分析

第十三章：价值链中主要企业的公司概况

竞争分析概述
BioLegend
BD Biosciences
ThermoFisher Scientific
Proteintech Group
Merck KGaA

第十四章附录

简介目录图表

The future of the global granulysin (GNLY) market looks promising with opportunities in the medical science and experiment markets. The global granulysin (GNLY) market is expected to reach an estimated $1,512 million by 2035 with a CAGR of 10.6% from 2026 to 2035. The major drivers for this market are the growing collaborations between biotech companies & research institutes, the rising adoption of GNLY biomarkers in diagnostic assay, and the increasing demand of granulysin in cancer treatment research.

Lucintel forecasts that, within the type category, 9 KDa GNLY is expected to witness higher growth over the forecast period.
Within the application category, medical science is expected to witness higher growth.
In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Granulysin (GNLY) Market

The granulysin (GNLY) market is experiencing rapid evolution driven by advances in immunology, biotechnology, and personalized medicine. As researchers deepen their understanding of GNLY's role in immune responses, new diagnostic and therapeutic applications are emerging. Market players are investing in innovative research to develop targeted treatments for infectious diseases, cancers, and inflammatory conditions. Additionally, regulatory frameworks and technological innovations are shaping the landscape, making GNLY-based solutions more accessible and effective. These developments are not only expanding the market but also transforming how healthcare providers approach immune-related disorders, ultimately leading to more personalized and effective patient care.

Increasing Research and Development Activities: Growing scientific interest in GNLY's role in immune response is fueling R&D efforts. Researchers are exploring its potential as a biomarker for disease diagnosis and prognosis, as well as a therapeutic target. This trend is leading to the development of novel diagnostic tools and treatments, attracting investments from biotech firms and academic institutions. The expanding R&D landscape is expected to accelerate the discovery of new applications, thereby broadening the market scope and improving patient outcomes.
Rising Prevalence of Infectious and Autoimmune Diseases: The global increase in infectious diseases such as tuberculosis and viral infections, along with autoimmune conditions, is driving demand for GNLY-based diagnostics and therapies. GNLY's ability to modulate immune responses makes it a promising candidate for managing these conditions. As healthcare systems seek more effective solutions, the market for GNLY-related products is expected to grow significantly, supported by increased awareness and diagnostic capabilities. This trend underscores the importance of GNLY in addressing unmet medical needs.
Technological Advancements in Biomarker Detection: Innovations in assay development, including high-throughput screening and multiplexing techniques, are enhancing the detection and quantification of GNLY. These technological improvements enable more accurate, rapid, and cost-effective diagnostics, facilitating early disease detection and personalized treatment plans. As these tools become more widespread, they will improve clinical decision-making and expand the application of GNLY in routine healthcare, thereby boosting market growth and adoption.
Growing Focus on Personalized Medicine: The shift towards personalized healthcare is emphasizing the importance of immune biomarkers like GNLY for tailored treatments. By understanding individual immune profiles, clinicians can optimize therapies for infectious diseases, cancers, and inflammatory disorders. This trend is encouraging the development of customized therapeutic approaches, increasing the demand for GNLY testing and targeted interventions. The market is thus moving towards more precise, patient-specific solutions, which promise better efficacy and reduced side effects.
Regulatory and Market Expansion: Regulatory agencies are increasingly recognizing the importance of immune biomarkers, leading to clearer pathways for approval of GNLY-based diagnostics and therapeutics. Concurrently, emerging markets are showing interest in adopting these innovations, driven by rising healthcare investments and infrastructure development. This regulatory support and market expansion are facilitating faster commercialization and wider adoption of GNLY-related products. As a result, the market is becoming more competitive and accessible, fostering innovation and global growth.

These trends are collectively reshaping the granulysin (GNLY) market by fostering innovation, expanding applications, and improving diagnostic and therapeutic options. The focus on personalized medicine, technological advancements, and regulatory support is driving market growth and transforming healthcare approaches to immune-related diseases. This evolution promises more effective, targeted, and accessible solutions, ultimately enhancing patient care worldwide.

Recent Developments in the Granulysin (GNLY) Market

The granulysin (GNLY) market is experiencing rapid growth driven by advances in immunotherapy and infectious disease treatment. Increasing research focus on GNLY's antimicrobial and antitumor properties is expanding its application scope. Rising prevalence of infectious diseases and cancers further fuels demand for GNLY-based therapies. Technological innovations in drug delivery and biomarker identification are enhancing market potential. Regulatory approvals and collaborations between biotech firms are accelerating product development. These developments collectively are transforming the GNLY landscape, offering new therapeutic avenues and improving patient outcomes worldwide.

Growing Research on GNLY Antimicrobial Properties: This development is expanding GNLY's application in infectious disease treatment, leading to novel therapies that can combat resistant pathogens. It enhances the market by attracting investments and fostering innovation in antimicrobial agents, ultimately improving healthcare outcomes and reducing disease burden globally.
Advances in Immunotherapy Utilizing GNLY: The integration of GNLY in immunotherapy strategies is boosting cancer treatment options. It enables targeted immune responses, increasing treatment efficacy and reducing side effects. This progress is attracting pharmaceutical companies, expanding market size, and encouraging new product development in oncology.
Rising Prevalence of Infectious Diseases and Cancers: The increasing incidence of diseases like HIV, tuberculosis, and various cancers is driving demand for GNLY-based solutions. This trend is creating a larger market for diagnostics and therapeutics, prompting investments in research and development, and fostering collaborations to meet unmet medical needs.
Technological Innovations in Drug Delivery and Biomarker Identification: New delivery systems and biomarker discovery are improving GNLY's stability, targeting, and efficacy. These innovations are making GNLY therapies more viable, expanding their clinical applications, and attracting funding, which accelerates market growth and broadens therapeutic options.
Regulatory Approvals and Strategic Collaborations: Recent approvals and partnerships are facilitating faster market entry for GNLY-based products. These developments are enhancing product pipelines, increasing investor confidence, and promoting commercialization, which collectively are propelling the market forward and encouraging further innovation.

The overall impact of these developments is a rapidly expanding GNLY market characterized by innovative therapies, increased investment, and broader clinical applications. This growth is expected to improve patient outcomes, address unmet medical needs, and stimulate further research and development, positioning GNLY as a vital component in future therapeutic strategies.

Strategic Growth Opportunities in the Granulysin (GNLY) Market

The granulysin (GNLY) market is experiencing rapid growth driven by increasing research into immune response mechanisms and the development of targeted therapies. Advances in biotechnology and rising prevalence of infectious diseases and cancers are fueling demand for GNLY-based diagnostics and therapeutics. Strategic collaborations, technological innovations, and expanding applications across healthcare sectors are creating significant opportunities for market players. This dynamic environment offers potential for substantial market expansion, improved patient outcomes, and enhanced understanding of immune system functions.

Growing Research and Development Activities in Immunology and Infectious Diseases: The increasing focus on immune response mechanisms has led to extensive R&D efforts exploring GNLY's role in combating infections and tumors. Pharmaceutical companies and research institutions are investing heavily in understanding GNLY's therapeutic potential, which is expected to drive new product development, clinical trials, and innovative treatment options, ultimately expanding the market.
Rising Prevalence of Infectious Diseases and Cancers Worldwide: The global burden of infectious diseases such as HIV, tuberculosis, and viral hepatitis, along with rising cancer incidences, is creating a demand for novel immunotherapies. GNLY's ability to target and destroy infected or malignant cells positions it as a promising candidate for therapeutic interventions, encouraging market growth through increased adoption and investment.
Advances in Biotechnology Enabling Targeted Delivery and Diagnostics: Innovations in nanotechnology, gene editing, and biomarker discovery are facilitating precise delivery of GNLY-based therapies and diagnostics. These technological advancements improve efficacy, reduce side effects, and enable early detection of diseases, thereby expanding the application scope and market size for GNLY-related products.
Increasing Collaborations Between Biotech Firms and healthcare Providers: Strategic partnerships and collaborations are accelerating GNLY research, product development, and commercialization. These alliances facilitate resource sharing, clinical validation, and regulatory approvals, which are crucial for market expansion. Such collaborations also enhance innovation pipelines and help penetrate emerging markets more effectively.
Growing Adoption of Immunotherapy in Clinical Practice: The shift towards immunotherapy as a standard treatment for various diseases is boosting GNLY's clinical application. Healthcare providers are increasingly integrating GNLY-based diagnostics and therapeutics into treatment regimens, supported by positive clinical outcomes and regulatory approvals, thereby driving market growth and broadening the scope of GNLY utilization.

The overall impact of these opportunities is poised to significantly enhance the growth trajectory of the granulysin (GNLY) market, fostering innovation, expanding application areas, and improving patient care outcomes globally

Granulysin (GNLY) Market Driver and Challenges

The granulysin (GNLY) market is influenced by a variety of technological, economic, and regulatory factors that shape its growth trajectory. Advances in immunology and biotechnology have enabled better understanding and utilization of GNLY in therapeutic applications. Economic factors such as increasing healthcare expenditure and rising prevalence of immune-related diseases drive demand. Regulatory frameworks around biopharmaceuticals impact market entry and development. Additionally, technological innovations in drug delivery and diagnostics further propel market expansion. However, challenges such as regulatory hurdles, high development costs, and market competition also pose significant barriers. Understanding these drivers and challenges is essential for stakeholders aiming to capitalize on the market's potential.

The factors responsible for driving the granulysin (GNLY) market include:-

Technological Advancements: The development of innovative biotechnological tools and techniques has significantly enhanced the ability to produce, analyze, and utilize GNLY. Advances in recombinant DNA technology, monoclonal antibody development, and diagnostic platforms have improved the precision and efficacy of GNLY-based therapies. These innovations facilitate faster drug development, better targeting of immune responses, and improved patient outcomes. As technology continues to evolve, the market benefits from increased research capabilities, reduced production costs, and expanded therapeutic applications, thereby fueling overall growth.
Rising Prevalence of Immune-Related Diseases: The increasing incidence of autoimmune disorders, cancers, and infectious diseases worldwide is a major driver for the GNLY market. GNLY plays a crucial role in immune responses, especially in cytotoxic T-cell and natural killer cell activity. As these diseases become more prevalent due to aging populations and lifestyle factors, demand for targeted immunotherapies involving GNLY rises. This trend encourages pharmaceutical companies and research institutions to invest in GNLY-based diagnostics and treatments, expanding market opportunities and encouraging innovation in this field.
Growing Investment in Biopharmaceutical Research: Governments, private investors, and pharmaceutical companies are significantly increasing funding for biopharmaceutical research, particularly in immunotherapy and personalized medicine. This financial support accelerates the discovery and development of GNLY-related therapies, diagnostics, and biomarkers. Increased R&D activity leads to new product pipelines, clinical trials, and regulatory approvals, which collectively boost market growth. Moreover, collaborations between academia and industry foster innovation, further expanding the scope and application of GNLY in various therapeutic areas.
Regulatory Support and Approvals: Favorable regulatory policies and accelerated approval pathways for biopharmaceuticals have positively impacted the GNLY market. Regulatory agencies are increasingly recognizing the importance of immunotherapies, leading to streamlined approval processes for innovative treatments. This support reduces time-to-market and encourages investment in GNLY-based products. Additionally, regulatory frameworks around personalized medicine and biomarker validation facilitate the integration of GNLY into clinical practice, thereby expanding its market reach and adoption.
Increasing Adoption of Personalized Medicine: The shift towards personalized and precision medicine is a key driver for the GNLY market. GNLY's role as a biomarker and therapeutic target aligns with the trend of tailoring treatments to individual patient profiles. This approach improves efficacy and reduces adverse effects, making GNLY-based therapies more attractive. The growing availability of genomic and proteomic data enables better patient stratification and targeted interventions, further propelling market growth. As healthcare systems increasingly adopt personalized strategies, demand for GNLY-related diagnostics and therapies is expected to rise significantly.

The challenges facing this Market include:-

Regulatory Hurdles and Approval Delays: Despite supportive policies, navigating complex regulatory pathways remains a significant challenge. Biopharmaceutical products like GNLY-based therapies require extensive clinical trials and validation, which can be time-consuming and costly. Regulatory agencies demand rigorous safety and efficacy data, often leading to delays in approval processes. These hurdles can increase development costs, extend time-to-market, and discourage investment, ultimately impacting market growth and the availability of innovative GNLY-based treatments.
High Development and Manufacturing Costs: The production of GNLY-based therapies involves sophisticated biotechnological processes, which are expensive and resource-intensive. The costs associated with research, clinical trials, and manufacturing scale-up are substantial, often limiting the number of companies able to participate in the market. These high costs can translate into expensive end products, restricting accessibility and adoption, especially in emerging markets. Overcoming cost barriers is essential for broader market penetration and sustainable growth.
Market Competition and Patent Challenges: The GNLY market faces intense competition from other immunotherapeutic agents and biopharmaceuticals targeting similar pathways. Patent expirations and intellectual property disputes can hinder innovation and market exclusivity. Additionally, the presence of multiple players with similar offerings can lead to price wars and reduced profit margins. Navigating competitive dynamics and securing robust patent protections are critical for companies to maintain market share and invest confidently in future developments.

The granulysin (GNLY) market is driven by technological innovations, rising disease prevalence, increased investment, regulatory support, and a shift towards personalized medicine. However, challenges such as regulatory delays, high costs, and intense competition pose significant hurdles. These factors collectively influence the pace of market growth, shaping opportunities and risks for stakeholders. Overall, the market's future depends on balancing innovation with strategic navigation of regulatory and economic barriers, ensuring sustainable development and expanded therapeutic applications.

List of Granulysin (GNLY) Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies granulysin (GNLY) companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the granulysin (GNLY) companies profiled in this report include-

BioLegend
BD Biosciences
ThermoFisher Scientific
Proteintech Group
Merck KGaA

Granulysin (GNLY) Market by Segment

The study includes a forecast for the global granulysin (GNLY) market by type, application, and region.

Granulysin (GNLY) Market by Type [Value from 2019 to 2035]:

9 KDa GNLY
15 KDa GNLY

Granulysin (GNLY) Market by Application [Value from 2019 to 2035]:

Medical Science
Experiment
Other

Granulysin (GNLY) Market by Region [Value from 2019 to 2035]:

North America
Europe
Asia Pacific
The Rest of the World

Country Wise Outlook for the Granulysin (GNLY) Market

The granulysin (GNLY) market has experienced significant growth driven by advancements in immunotherapy, infectious disease treatment, and cancer research. As global health challenges evolve, countries are investing in innovative therapies that leverage granulysin's antimicrobial and antitumor properties. Regulatory approvals, increased research funding, and technological innovations are shaping the market landscape across major regions. The United States, China, Germany, India, and Japan are at the forefront of these developments, each contributing uniquely to the global progress in granulysin-based therapies and diagnostics.

United States: The US market has seen rapid advancements with increased clinical trials exploring granulysin's role in cancer immunotherapy and infectious diseases. Leading biotech firms and research institutions are developing granulysin-based treatments, supported by substantial government funding and regulatory approvals. The focus is on personalized medicine approaches, with several products in late-stage development. The US also benefits from a robust healthcare infrastructure that facilitates rapid adoption of new therapies, boosting market growth.
China: China is rapidly expanding its granulysin research and application scope, driven by government initiatives to boost biotech innovation. Local companies are investing heavily in developing granulysin-based diagnostics and therapeutics, especially for infectious diseases like tuberculosis and viral infections. The country's large patient population provides a significant market for clinical trials and product commercialization. Regulatory frameworks are evolving to support faster approval processes, fostering a conducive environment for market expansion.
Germany: Germany's market is characterized by strong research collaborations between academia and industry, focusing on granulysin's immunomodulatory properties. The country emphasizes precision medicine and has integrated granulysin-based diagnostics into its healthcare system. Germany's advanced biotech sector and stringent regulatory standards ensure high-quality product development. The market is also supported by European Union funding programs, which facilitate innovation and clinical research in this domain.
India: India is witnessing a growing interest in granulysin research, particularly for infectious diseases prevalent in the region. The government's focus on healthcare infrastructure and affordable therapeutics has spurred local startups and research institutions to explore granulysin applications. Clinical trials are underway for granulysin-based treatments targeting tuberculosis and other infectious diseases. The expanding healthcare market and increasing awareness about immunotherapies are expected to drive future growth in this sector.
Japan: Japan has made notable progress in granulysin research, especially in cancer immunotherapy and infectious disease management. The country's advanced biotech ecosystem and strong regulatory environment support the development and commercialization of granulysin-based products. Japanese research institutions are collaborating internationally to explore innovative applications. The government's strategic initiatives aim to integrate granulysin therapies into mainstream healthcare, fostering innovation and market expansion in the region.

Features of the Global Granulysin (GNLY) Market

Market Size Estimates: Granulysin (GNLY) market size estimation in terms of value ($M).
Trend and Forecast Analysis: Market trends (2019 to 2025) and forecast (2026 to 2035) by various segments and regions.
Segmentation Analysis: Granulysin (GNLY) market size by type, application, and region in terms of value ($M).
Regional Analysis: Granulysin (GNLY) market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the granulysin (GNLY) market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the granulysin (GNLY) market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the granulysin (GNLY) market by type (9 KDa GNLY and 15 KDa GNLY), application (medical science, experiment, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 7 years and what has its impact been on the industry?

1. Executive Summary

2. Market Overview

2.1 Background and Classifications
2.2 Supply Chain

3. Market Trends & Forecast Analysis

3.1 Macroeconomic Trends and Forecasts
3.2 Industry Drivers and Challenges
3.3 PESTLE Analysis
3.4 Patent Analysis
3.5 Regulatory Environment

4. Global Granulysin (GNLY) Market by Type

4.1 Overview
4.2 Attractiveness Analysis by Type
4.3 9 KDa GNLY : Trends and Forecast (2019-2035)
4.4 15 KDa GNLY : Trends and Forecast (2019-2035)

5. Global Granulysin (GNLY) Market by Application

5.1 Overview
5.2 Attractiveness Analysis by Application
5.3 Medical Science : Trends and Forecast (2019-2035)
5.4 Experiment : Trends and Forecast (2019-2035)
5.5 Other : Trends and Forecast (2019-2035)

6. Regional Analysis

6.1 Overview
6.2 Global Granulysin (GNLY) Market by Region

7. North American Granulysin (GNLY) Market

7.1 Overview
7.2 North American Granulysin (GNLY) Market by Type
7.3 North American Granulysin (GNLY) Market by Application
7.4 The United States Granulysin (GNLY) Market
7.5 Canadian Granulysin (GNLY) Market
7.6 Mexican Granulysin (GNLY) Market

8. European Granulysin (GNLY) Market

8.1 Overview
8.2 European Granulysin (GNLY) Market by Type
8.3 European Granulysin (GNLY) Market by Application
8.4 German Granulysin (GNLY) Market
8.5 French Granulysin (GNLY) Market
8.6 Italian Granulysin (GNLY) Market
8.7 Spanish Granulysin (GNLY) Market
8.8 The United Kingdom Granulysin (GNLY) Market

9. APAC Granulysin (GNLY) Market

9.1 Overview
9.2 APAC Granulysin (GNLY) Market by Type
9.3 APAC Granulysin (GNLY) Market by Application
9.4 Chinese Granulysin (GNLY) Market
9.5 Indian Granulysin (GNLY) Market
9.6 Japanese Granulysin (GNLY) Market
9.7 South Korean Granulysin (GNLY) Market
9.8 Indonesian Granulysin (GNLY) Market

10. ROW Granulysin (GNLY) Market

10.1 Overview
10.2 ROW Granulysin (GNLY) Market by Type
10.3 ROW Granulysin (GNLY) Market by Application
10.4 Middle Eastern Granulysin (GNLY) Market
10.5 South American Granulysin (GNLY) Market
10.6 African Granulysin (GNLY) Market

11. Competitor Analysis

11.1 Product Portfolio Analysis
11.2 Operational Integration
11.3 Porter's Five Forces Analysis
- Competitive Rivalry
- Bargaining Power of Buyers
- Bargaining Power of Suppliers
- Threat of Substitutes
- Threat of New Entrants
11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

12.1 Value Chain Analysis
12.2 Growth Opportunity Analysis
- 12.2.1 Growth Opportunity by Type
- 12.2.2 Growth Opportunity by Application
12.3 Emerging Trends in the Global Granulysin (GNLY) Market
12.4 Strategic Analysis
- 12.4.1 New Product Development
- 12.4.2 Certification and Licensing
- 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

13.1 Competitive Analysis Overview
13.2 BioLegend
- Company Overview
- Granulysin (GNLY) Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.3 BD Biosciences
- Company Overview
- Granulysin (GNLY) Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.4 ThermoFisher Scientific
- Company Overview
- Granulysin (GNLY) Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.5 Proteintech Group
- Company Overview
- Granulysin (GNLY) Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing
13.6 Merck KGaA
- Company Overview
- Granulysin (GNLY) Market Business Overview
- New Product Development
- Merger, Acquisition, and Collaboration
- Certification and Licensing

14. Appendix

14.1 List of Figures
14.2 List of Tables
14.3 Research Methodology
14.4 Disclaimer
14.5 Copyright
14.6 Abbreviations and Technical Units
14.7 About Us
14.8 Contact Us

简介目录图表

List of Figures

Figure 1.1: Trends and Forecast for the Global Granulysin (GNLY) Market
Figure 2.1: Usage of Granulysin (GNLY) Market
Figure 2.2: Classification of the Global Granulysin (GNLY) Market
Figure 2.3: Supply Chain of the Global Granulysin (GNLY) Market
Figure 3.1: Trends of the Global GDP Growth Rate
Figure 3.2: Trends of the Global Population Growth Rate
Figure 3.3: Trends of the Global Inflation Rate
Figure 3.4: Trends of the Global Unemployment Rate
Figure 3.5: Trends of the Regional GDP Growth Rate
Figure 3.6: Trends of the Regional Population Growth Rate
Figure 3.7: Trends of the Regional Inflation Rate
Figure 3.8: Trends of the Regional Unemployment Rate
Figure 3.9: Trends of Regional Per Capita Income
Figure 3.10: Forecast for the Global GDP Growth Rate
Figure 3.11: Forecast for the Global Population Growth Rate
Figure 3.12: Forecast for the Global Inflation Rate
Figure 3.13: Forecast for the Global Unemployment Rate
Figure 3.14: Forecast for the Regional GDP Growth Rate
Figure 3.15: Forecast for the Regional Population Growth Rate
Figure 3.16: Forecast for the Regional Inflation Rate
Figure 3.17: Forecast for the Regional Unemployment Rate
Figure 3.18: Forecast for Regional Per Capita Income
Figure 3.19: Driver and Challenges of the Granulysin (GNLY) Market
Figure 4.1: Global Granulysin (GNLY) Market by Type in 2019, 2025, and 2035
Figure 4.2: Trends of the Global Granulysin (GNLY) Market ($M) by Type
Figure 4.3: Forecast for the Global Granulysin (GNLY) Market ($M) by Type
Figure 4.4: Trends and Forecast for 9 KDa GNLY in the Global Granulysin (GNLY) Market (2019-2035)
Figure 4.5: Trends and Forecast for 15 KDa GNLY in the Global Granulysin (GNLY) Market (2019-2035)
Figure 5.1: Global Granulysin (GNLY) Market by Application in 2019, 2025, and 2035
Figure 5.2: Trends of the Global Granulysin (GNLY) Market ($M) by Application
Figure 5.3: Forecast for the Global Granulysin (GNLY) Market ($M) by Application
Figure 5.4: Trends and Forecast for Medical Science in the Global Granulysin (GNLY) Market (2019-2035)
Figure 5.5: Trends and Forecast for Experiment in the Global Granulysin (GNLY) Market (2019-2035)
Figure 5.6: Trends and Forecast for Other in the Global Granulysin (GNLY) Market (2019-2035)
Figure 6.1: Trends of the Global Granulysin (GNLY) Market ($M) by Region (2019-2025)
Figure 6.2: Forecast for the Global Granulysin (GNLY) Market ($M) by Region (2026-2035)
Figure 7.1: Trends and Forecast for the North American Granulysin (GNLY) Market (2019-2035)
Figure 7.2: North American Granulysin (GNLY) Market by Type in 2019, 2025, and 2035
Figure 7.3: Trends of the North American Granulysin (GNLY) Market ($M) by Type (2019-2025)
Figure 7.4: Forecast for the North American Granulysin (GNLY) Market ($M) by Type (2026-2035)
Figure 7.5: North American Granulysin (GNLY) Market by Application in 2019, 2025, and 2035
Figure 7.6: Trends of the North American Granulysin (GNLY) Market ($M) by Application (2019-2025)
Figure 7.7: Forecast for the North American Granulysin (GNLY) Market ($M) by Application (2026-2035)
Figure 7.8: Trends and Forecast for the United States Granulysin (GNLY) Market ($M) (2019-2035)
Figure 7.9: Trends and Forecast for the Mexican Granulysin (GNLY) Market ($M) (2019-2035)
Figure 7.10: Trends and Forecast for the Canadian Granulysin (GNLY) Market ($M) (2019-2035)
Figure 8.1: Trends and Forecast for the European Granulysin (GNLY) Market (2019-2035)
Figure 8.2: European Granulysin (GNLY) Market by Type in 2019, 2025, and 2035
Figure 8.3: Trends of the European Granulysin (GNLY) Market ($M) by Type (2019-2025)
Figure 8.4: Forecast for the European Granulysin (GNLY) Market ($M) by Type (2026-2035)
Figure 8.5: European Granulysin (GNLY) Market by Application in 2019, 2025, and 2035
Figure 8.6: Trends of the European Granulysin (GNLY) Market ($M) by Application (2019-2025)
Figure 8.7: Forecast for the European Granulysin (GNLY) Market ($M) by Application (2026-2035)
Figure 8.8: Trends and Forecast for the German Granulysin (GNLY) Market ($M) (2019-2035)
Figure 8.9: Trends and Forecast for the French Granulysin (GNLY) Market ($M) (2019-2035)
Figure 8.10: Trends and Forecast for the Spanish Granulysin (GNLY) Market ($M) (2019-2035)
Figure 8.11: Trends and Forecast for the Italian Granulysin (GNLY) Market ($M) (2019-2035)
Figure 8.12: Trends and Forecast for the United Kingdom Granulysin (GNLY) Market ($M) (2019-2035)
Figure 9.1: Trends and Forecast for the APAC Granulysin (GNLY) Market (2019-2035)
Figure 9.2: APAC Granulysin (GNLY) Market by Type in 2019, 2025, and 2035
Figure 9.3: Trends of the APAC Granulysin (GNLY) Market ($M) by Type (2019-2025)
Figure 9.4: Forecast for the APAC Granulysin (GNLY) Market ($M) by Type (2026-2035)
Figure 9.5: APAC Granulysin (GNLY) Market by Application in 2019, 2025, and 2035
Figure 9.6: Trends of the APAC Granulysin (GNLY) Market ($M) by Application (2019-2025)
Figure 9.7: Forecast for the APAC Granulysin (GNLY) Market ($M) by Application (2026-2035)
Figure 9.8: Trends and Forecast for the Japanese Granulysin (GNLY) Market ($M) (2019-2035)
Figure 9.9: Trends and Forecast for the Indian Granulysin (GNLY) Market ($M) (2019-2035)
Figure 9.10: Trends and Forecast for the Chinese Granulysin (GNLY) Market ($M) (2019-2035)
Figure 9.11: Trends and Forecast for the South Korean Granulysin (GNLY) Market ($M) (2019-2035)
Figure 9.12: Trends and Forecast for the Indonesian Granulysin (GNLY) Market ($M) (2019-2035)
Figure 10.1: Trends and Forecast for the ROW Granulysin (GNLY) Market (2019-2035)
Figure 10.2: ROW Granulysin (GNLY) Market by Type in 2019, 2025, and 2035
Figure 10.3: Trends of the ROW Granulysin (GNLY) Market ($M) by Type (2019-2025)
Figure 10.4: Forecast for the ROW Granulysin (GNLY) Market ($M) by Type (2026-2035)
Figure 10.5: ROW Granulysin (GNLY) Market by Application in 2019, 2025, and 2035
Figure 10.6: Trends of the ROW Granulysin (GNLY) Market ($M) by Application (2019-2025)
Figure 10.7: Forecast for the ROW Granulysin (GNLY) Market ($M) by Application (2026-2035)
Figure 10.8: Trends and Forecast for the Middle Eastern Granulysin (GNLY) Market ($M) (2019-2035)
Figure 10.9: Trends and Forecast for the South American Granulysin (GNLY) Market ($M) (2019-2035)
Figure 10.10: Trends and Forecast for the African Granulysin (GNLY) Market ($M) (2019-2035)
Figure 11.1: Porter's Five Forces Analysis of the Global Granulysin (GNLY) Market
Figure 11.2: Market Share (%) of Top Players in the Global Granulysin (GNLY) Market (2025)
Figure 12.1: Growth Opportunities for the Global Granulysin (GNLY) Market by Type
Figure 12.2: Growth Opportunities for the Global Granulysin (GNLY) Market by Application
Figure 12.3: Growth Opportunities for the Global Granulysin (GNLY) Market by Region
Figure 12.4: Emerging Trends in the Global Granulysin (GNLY) Market

List of Tables

Table 1.1: Growth Rate (%, 2024-2025) and CAGR (%, 2026-2035) of the Granulysin (GNLY) Market by Type and Application
Table 1.2: Attractiveness Analysis for the Granulysin (GNLY) Market by Region
Table 1.3: Global Granulysin (GNLY) Market Parameters and Attributes
Table 3.1: Trends of the Global Granulysin (GNLY) Market (2019-2025)
Table 3.2: Forecast for the Global Granulysin (GNLY) Market (2026-2035)
Table 4.1: Attractiveness Analysis for the Global Granulysin (GNLY) Market by Type
Table 4.2: Market Size and CAGR of Various Type in the Global Granulysin (GNLY) Market (2019-2025)
Table 4.3: Market Size and CAGR of Various Type in the Global Granulysin (GNLY) Market (2026-2035)
Table 4.4: Trends of 9 KDa GNLY in the Global Granulysin (GNLY) Market (2019-2025)
Table 4.5: Forecast for 9 KDa GNLY in the Global Granulysin (GNLY) Market (2026-2035)
Table 4.6: Trends of 15 KDa GNLY in the Global Granulysin (GNLY) Market (2019-2025)
Table 4.7: Forecast for 15 KDa GNLY in the Global Granulysin (GNLY) Market (2026-2035)
Table 5.1: Attractiveness Analysis for the Global Granulysin (GNLY) Market by Application
Table 5.2: Market Size and CAGR of Various Application in the Global Granulysin (GNLY) Market (2019-2025)
Table 5.3: Market Size and CAGR of Various Application in the Global Granulysin (GNLY) Market (2026-2035)
Table 5.4: Trends of Medical Science in the Global Granulysin (GNLY) Market (2019-2025)
Table 5.5: Forecast for Medical Science in the Global Granulysin (GNLY) Market (2026-2035)
Table 5.6: Trends of Experiment in the Global Granulysin (GNLY) Market (2019-2025)
Table 5.7: Forecast for Experiment in the Global Granulysin (GNLY) Market (2026-2035)
Table 5.8: Trends of Other in the Global Granulysin (GNLY) Market (2019-2025)
Table 5.9: Forecast for Other in the Global Granulysin (GNLY) Market (2026-2035)
Table 6.1: Market Size and CAGR of Various Regions in the Global Granulysin (GNLY) Market (2019-2025)
Table 6.2: Market Size and CAGR of Various Regions in the Global Granulysin (GNLY) Market (2026-2035)
Table 7.1: Trends of the North American Granulysin (GNLY) Market (2019-2025)
Table 7.2: Forecast for the North American Granulysin (GNLY) Market (2026-2035)
Table 7.3: Market Size and CAGR of Various Type in the North American Granulysin (GNLY) Market (2019-2025)
Table 7.4: Market Size and CAGR of Various Type in the North American Granulysin (GNLY) Market (2026-2035)
Table 7.5: Market Size and CAGR of Various Application in the North American Granulysin (GNLY) Market (2019-2025)
Table 7.6: Market Size and CAGR of Various Application in the North American Granulysin (GNLY) Market (2026-2035)
Table 7.7: Trends and Forecast for the United States Granulysin (GNLY) Market (2019-2035)
Table 7.8: Trends and Forecast for the Mexican Granulysin (GNLY) Market (2019-2035)
Table 7.9: Trends and Forecast for the Canadian Granulysin (GNLY) Market (2019-2035)
Table 8.1: Trends of the European Granulysin (GNLY) Market (2019-2025)
Table 8.2: Forecast for the European Granulysin (GNLY) Market (2026-2035)
Table 8.3: Market Size and CAGR of Various Type in the European Granulysin (GNLY) Market (2019-2025)
Table 8.4: Market Size and CAGR of Various Type in the European Granulysin (GNLY) Market (2026-2035)
Table 8.5: Market Size and CAGR of Various Application in the European Granulysin (GNLY) Market (2019-2025)
Table 8.6: Market Size and CAGR of Various Application in the European Granulysin (GNLY) Market (2026-2035)
Table 8.7: Trends and Forecast for the German Granulysin (GNLY) Market (2019-2035)
Table 8.8: Trends and Forecast for the French Granulysin (GNLY) Market (2019-2035)
Table 8.9: Trends and Forecast for the Spanish Granulysin (GNLY) Market (2019-2035)
Table 8.10: Trends and Forecast for the Italian Granulysin (GNLY) Market (2019-2035)
Table 8.11: Trends and Forecast for the United Kingdom Granulysin (GNLY) Market (2019-2035)
Table 9.1: Trends of the APAC Granulysin (GNLY) Market (2019-2025)
Table 9.2: Forecast for the APAC Granulysin (GNLY) Market (2026-2035)
Table 9.3: Market Size and CAGR of Various Type in the APAC Granulysin (GNLY) Market (2019-2025)
Table 9.4: Market Size and CAGR of Various Type in the APAC Granulysin (GNLY) Market (2026-2035)
Table 9.5: Market Size and CAGR of Various Application in the APAC Granulysin (GNLY) Market (2019-2025)
Table 9.6: Market Size and CAGR of Various Application in the APAC Granulysin (GNLY) Market (2026-2035)
Table 9.7: Trends and Forecast for the Japanese Granulysin (GNLY) Market (2019-2035)
Table 9.8: Trends and Forecast for the Indian Granulysin (GNLY) Market (2019-2035)
Table 9.9: Trends and Forecast for the Chinese Granulysin (GNLY) Market (2019-2035)
Table 9.10: Trends and Forecast for the South Korean Granulysin (GNLY) Market (2019-2035)
Table 9.11: Trends and Forecast for the Indonesian Granulysin (GNLY) Market (2019-2035)
Table 10.1: Trends of the ROW Granulysin (GNLY) Market (2019-2025)
Table 10.2: Forecast for the ROW Granulysin (GNLY) Market (2026-2035)
Table 10.3: Market Size and CAGR of Various Type in the ROW Granulysin (GNLY) Market (2019-2025)
Table 10.4: Market Size and CAGR of Various Type in the ROW Granulysin (GNLY) Market (2026-2035)
Table 10.5: Market Size and CAGR of Various Application in the ROW Granulysin (GNLY) Market (2019-2025)
Table 10.6: Market Size and CAGR of Various Application in the ROW Granulysin (GNLY) Market (2026-2035)
Table 10.7: Trends and Forecast for the Middle Eastern Granulysin (GNLY) Market (2019-2035)
Table 10.8: Trends and Forecast for the South American Granulysin (GNLY) Market (2019-2035)
Table 10.9: Trends and Forecast for the African Granulysin (GNLY) Market (2019-2035)
Table 11.1: Product Mapping of Granulysin (GNLY) Suppliers Based on Segments
Table 11.2: Operational Integration of Granulysin (GNLY) Manufacturers
Table 11.3: Rankings of Suppliers Based on Granulysin (GNLY) Revenue
Table 12.1: New Product Launches by Major Granulysin (GNLY) Producers (2019-2025)
Table 12.2: Certification Acquired by Major Competitor in the Global Granulysin (GNLY) Market

02-2729-4219

+886-2-2729-4219

License/价格

粒细胞集落刺激因子（GNLY）市场报告：趋势、预测和竞争分析（至2035年）

Granulysin (GNLY) Market Report: Trends, Forecast and Competitive Analysis to 2035

目录

第一章：执行摘要

第二章市场概览

第三章市场趋势与预测分析

第四章：全球颗粒红（GNLY）市场：按类型划分

第五章全球颗粒红（GNLY）市场：依应用划分

第六章区域分析

第七章：北美洲颗粒酶（GNLY）市场

第八章：欧洲颗粒剂（GNLY）市场

第九章：亚太地区粒诺利辛（GNLY）市场